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Abstract Cardiovascular disease (CVD) still represents
the leading cause of mortality and morbidity worldwide.
Despite considerable improvements in the prognosis of
CVD and the significant reduction of CVD mortality ob-
tained during the past half century, patients developing
CVD, even though satisfactorily treated, still carry coro-
nary artery disease and remain at risk for advanced CVD.
Thus, the healthcare and socioeconomic burden linked to
CVD remains high. As a result, more effective CVD pre-
vention strategies remain crucial. ‘Population strategies’
and ‘high-risk’ approaches both have limitations and have
often been viewed as alternative solutions. This persistent
dualism could be overcome with the promotion of inte-
grated prevention strategies based on a systematic evalua-
tion of the total risk of disease, at both a population and an
individual level. New approaches are also needed to reach
people earlier in the course of the vascular disease and,
possibly, to prevent risk factors and reduce CVD clinical
manifestation.
Key Points
Since cardiovascular disease (CVD) remains the
leading cause of death worldwide despite the recent
advantages in cardiovascular diagnosis and therapy,
a more efficient approach to CVD prevention is
necessary.
A possible improvement could be derived from a
strategy that integrates the two traditional preventive
approaches, the ‘high-risk approach’ and the
‘population approach’.
In this regard, it could be reconsidered a so-called
‘polypill’ approach, which could be widely
applicable, especially in low and middle-income
countries.
1 The Toll of Cardiovascular Disease at the Dawn
of the Third Millennium
Cardiovascular disease (CVD) remains the main cause of
death in Europe this century and a great cause of morbidity,
with coronary artery disease (CAD) and stroke representing
the most common clinical manifestations [1]. Recently,
there is also worrying evidence that the former decline in
CVD mortality is generally levelling off, particularly
among young adults [2–4], and hospital discharge rates for
CVD have increased in the majority of European countries
[5].
& Allegra Battistoni
alle.battistoni@gmail.com
Massimo Volpe
massimo.volpe@uniroma1.it
1 Division of Cardiology, Department of Clinical and
Molecular Medicine, Faculty of Medicine and Psychology,
Sapienza University of Rome, Ospedale Sant’Andrea,
Via di Grottarossa 1035-1039, 00189 Rome, Italy
2 IRCCS Neuromed, Pozzilli, IS, Italy
Am J Cardiovasc Drugs
DOI 10.1007/s40256-015-0114-7
Author's personal copy
Moreover, according to the World Health Organization
(WHO), 80 % of the mortality attributable to non-com-
municable diseases (NCDs) occurs in low- and middle-
income countries (LMICs), and CVD accounts for most of
this burden. For example, the mortality attributable to CVD
in Africa, South-East Asia, and the Eastern Mediterranean
regions is projected to increase from 20 to 35 % by the year
2020 [6]. It is estimated that more than 30 million adults in
Africa have hypertension, and 75 % of all deaths in Africa
will be attributable to hypertension by the year 2020 [7].
In coming decades, estimated disability-adjusted life-
years (DALYs) is expected to rise from a loss of 85 million
DALYs in 1990 to a loss of[150 million DALYs globally
in 2020, with CVD remaining the leading cause of pro-
ductivity loss [8].
Although early CVD mortality may have declined by
75 % during the past half century [9], survivors still have
CAD and remain at risk for subsequent episodes of is-
chemic myocardial damage, left ventricular dysfunction,
atrial fibrillation, and heart failure (HF). Thus, one might
conclude that, with the continued increase in life ex-
pectancy and progressive aging of the population, chronic
CVD, such as HF, will remain a major health and socio-
economic problem [7]. As a consequence, the socio-eco-
nomic burden remains heavy: in 2006, total CVD costs in
the EU exceeded €190 billion [4].
The escalating epidemics of hypertension, diabetes, and
obesity, and the increasing number of people who are
adopting sedentary lifestyles and unhealthy diets, threaten
to stall or even reverse the favorable gains related to better
trends in individual risk factor (RF) management [10–15].
Data from the WHO predict that patients at high CVD risk
will increase from the current 300 million to 600 million in
2020 [16]. The adverse trend in some of these established
RFs could be identified as the main reason for the stalling
of the decline in CVD death rate and the growing level of
CVD morbidity [2–4, 13].
2 Cardiovascular Prevention Strategies:
An Historical Dualism Between Population
and High-Risk Approaches
With such a background and an undeniably increasing
number of patients with chronic NCDs, we, as treating
physicians, cannot be satisfied with the outcomes achieved
by CVD prevention strategies so far. Evidently, it is vitally
important to contemplate the possibility of medical inter-
ventions at a preclinical level to avoid even early devel-
opment of the disease and the subsequent development of
cardiovascular (CV) events. Identification of RFs, abnor-
mal biomarkers and markers of target organ damage should
prompt earlier interventions [17, 18].
Over 20 years ago, Geoffrey Rose, one of the ‘fathers’
of preventive medicine, identified a key message that, de-
spite that CV high-risk individuals gain most from pre-
ventive measures, the greatest number of deaths due to
CVD occurs in low- or medium-risk individuals, simply
because they represent a much larger group [15, 19].
Therefore, primary prevention of CVD may benefit from
two complementary approaches, ‘the mass or population
approach’ and the ‘high-risk individual approach’. The first
aims to control the determinants of CVD in the entire
population. Shifting the RF distribution in a more favorable
way through community-based interventions is most ap-
propriate for reducing the incidence of disease. It has tra-
ditionally focused on lifestyle modifications through health
education, societal, and economic measures to reduce ex-
posures and encourage ‘healthy’ behaviors [20]. The ‘mass
approach’ leads to the ‘prevention paradox’: ‘a measure
that brings large benefits to the community offers little to
each participating individual’. This implies that we should
not expect too much in terms of individual health benefits
[15, 21].
The second approach, in turn, aims to identify indi-
viduals at high risk and reduce their susceptibility to CVD
[18, 22]. For a long time the population strategy has been
considered to be more cost effective than the high-risk
approach, and the two approaches have been viewed as
substantially alternative. Since the introduction of highly
effective lipid-lowering drugs, improvements in smoking-
cessation programs, and the lower costs and ease of access
to antihypertensive drugs, the effectiveness of the high-risk
approach has become less ‘complex’ and more widely
adopted [23].
3 Overcoming the Dualism
Nowadays, consensus is growing that a larger preventive
effect can be achieved when the ‘population’ and the
‘high-risk’ strategies are combined (Fig. 1). The current
approaches to primary prevention include public health
advice and treatment of an individual’s RFs by health-
care providers. However, even this kind of global strat-
egy can have considerable limitations. In fact, global
prevention should include multiple strategies: health
policy, environmental changes, and individual behavioral
changes. Lifestyle interventions are attractive because of
their inherent ‘natural’ appeal, perceived low cost, sim-
plicity, and safety. However, behavioral interventions to
modify individual lifestyles are costly, generally have
only a modest and unsustainable impact, and have often
resulted in marginal measurable benefits in reducing
CVD events when tested in large, long-term trials
[24, 25].
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Furthermore, public health advice to exercise, eat
healthier, and quit smoking has largely been shown to be
ineffective, with the possible exception of smoking cessa-
tion (smoking rates among adults have declined by almost
50 % over the past 40 years), probably thanks to popula-
tion-wide fiscal and legislative interventions [26]. A recent
review showed that health education or intervention pro-
grams in primary care settings among patients at low risk
still appear to be of little benefit [27].
On the other hand, ‘high-risk’ strategies need to be
widely used to have appreciable general impact [28], which
means appropriate screening and full adherence to therapy
of ‘high-risk’ individuals [29]. However, in clinical prac-
tice, we are far from achieving this level of intervention.
For example, in the USA, approximately 60 % of patients
with diabetes (high-risk patients) still do not receive a
lipid-lowering agent [30], and less than one-third of pa-
tients with chronic kidney disease receive lipid-lowering
drugs and only 40 % are at low-density lipoprotein
cholesterol (LDL-C) goal [31]. Personalized care does not
reach everyone, especially in the poorly organized primary
care environment of some developed countries. In the
PURE (Prospective Urban Rural Epidemiology) study, in-
volving 154,000 individuals from 628 communities and 17
countries, 41 % of participants had hypertension. Of those
with hypertension, only 46 % were aware of having
elevated blood pressure (BP) and only 41 % were receiving
pharmacological treatment. As a consequence, merely
13 % of all hypertensive patients had their BP controlled to
recommended values [32].
The issue raised by Rose about the relative benefits of a
population-wide approach to intervention compared with a
targeted approach has been quantitatively considered. The
two approaches have been explored using cost-effective-
ness simulations for each approach. As a specific example,
the two approaches have been compared with regards to BP
to reduce CVD [33]. The risk curve for CVD based on the
Framingham equation was applied to a real population
distribution of high BP. A targeted intervention and
population-wide intervention for high BP was then applied.
The effects of each intervention in relation to the change in
BP distributions based on realistic values of BP reductions
from medication (for the targeted approach) and from the
results of a population-wide intervention (for the popula-
tion-wide approach) were modelled. The population-wide
treatments costing $US100 or less are more beneficial and
cost effective than any of the targeted treatments. However,
the targeted treatments with lower cut-offs for treatment
provided more advantage for the benefit fraction and the
disease prevented (systolic BP [SBP] [140 mmHg). For
the higher costs of the population-wide treatment, the cut-
off chosen for BP determines the relative benefit/cost ef-
fectiveness of the two approaches. In all the targeted and
population-wide intervention scenarios, the benefit exceeds
Fig. 1 Integrated interventions to optimize cardiovascular disease prevention. CVD cardiovascular disease, HDL-C high-density lipoprotein
cholesterol LDL-C low-density lipoprotein cholesterol
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the cost for a population-wide treatment with a cost of only
$US60 per person or less.
Since high-income western countries started to system-
atically fight CVD many decades ago, much experience has
been developed to better understand this challenge, and
health systems have been progressively adjusted. In
LMICs, the rapidity of changes, the scale of these changes,
and the large populations involved have rapidly outstripped
healthcare systems, and available infrastructures are still
unable to cope with the growing burden of CVD. Thus, the
LMIC cannot simply reproduce the approaches taken by
high-income countries. They must instead develop more
cost-effective and equitable ways of countering NCDs [34].
The evidence for the cost effectiveness of interventions in
LMICs is growing but remains insufficient and is often
restricted to pharmacological interventions [35]. Identifi-
cation of individuals at high risk for CV events will also be
needed, and, in some resource-limited settings, non-
laboratory-based methods are preferred [36, 37]. For in-
stance, in a recent modelling study, Wald et al. [38]
showed that screening for future events by age alone
yielded detection and false-positive rates comparable with
the accuracy of current more expensive methods [38].
4 Treatment of Risk Factors at a Preclinical Level
and Lifetime Risk
With regard to CV risk, the fact that considerable vascular
damage can occur even before RFs are identified and
treated is crucial. New approaches are needed to reach
more people earlier in the course of CVD. The vascular
damage that leads to CV accidents begins years before RFs
such as high BP and cholesterol reach diagnostic thresholds
for hypercholesterolemia and hypertension, and years be-
fore the first clinical event. Therefore, to prevent diseases,
RFs need to be addressed before the age at which the CVD
incidence peaks and such efforts should be continued in-
definitely [39]. With this regard a clinical trial has shown
that treatment with an angiotensin-receptor blocker may
delay clinically defined hypertension from emerging in
individuals with prehypertension [40].
Similarly, in a recent meta-analysis of more than
300,000 subjects, a Mendelian randomization approach
was used to estimate the clinical benefit of lowering LDL
early in life. As a proxy, the authors used a treatment that
would decrease LDL-C beginning at birth, which is the
inherited allocation for the protective genotype (for nine
single-nucleotide polymorphisms [SNPs] associated with
lower LDL-C). Results showed that a low LDL-C con-
centration, following this random natural allocation, de-
creased the risk of CAD by 54.5 % for each mmol/l LDL-C
reduction. Comparatively, for the same level of LDL
decrease, statin therapy started later in life would only
reduce CAD by 24 %. The authors concluded that exposure
to LDL-C-lowering drugs earlier in life is associated with a
greater reduction of CAD compared with the current
practice of starting lipid-lowering pharmacological strate-
gies later in life [41]. The deleterious effects of early and
long-term exposure to dyslipidemia were studied in the
CARDIA (Coronary Artery Risk Development In young
Adults) study, wherein authors compared the risk of
coronary calcium (an intermediate surrogate for CAD) in
subjects with optimal LDL concentration\70 mg/dl. They
found that, in healthy subjects exposed to slightly subop-
timal LDL-C (70–99 mg/dl), the presence of coronary
calcium was 1.5-fold higher, and subjects with concentra-
tions marginally higher (100–129 mg/dl) had a sig-
nificantly higher risk of coronary calcium of 2.4-fold [42].
Moreover, results from the large MEGA (Management of
Elevated Cholesterol in the Primary Prevention Group of
Adult Japanese) trial also showed similar trends. Irrespec-
tive of their level of risk, all patients seen in clinical
practice showed a clear benefit from statin therapy, even at
low doses, such as pravastatin 10 mg [43]. Therefore, this
pharmacological approach could paradoxically be cost ef-
fective when not only reserved to the high-risk population
[44].
The significance of lifetime CV risk estimate plays a
major role in this frame. Indeed, short-term risk estimates
have important limitations, classifying most adults aged
\50 years and most women as being low risk, regardless
of RF burden [45, 46]. In contrast, estimates of lifetime risk
provide a significantly different classification of individual
risk and probably represent a real snapshot of the indi-
vidual susceptibility to CV events during the following
decades. Therefore, national guidelines in both the USA
and Europe have recently encouraged the use of long-term
or lifetime risk as an adjunct to short-term risk communi-
cation in primary prevention.
Several studies have examined the association between
short-term perceived and predicted risk for CVD [47–50].
Most of these studies observed that incorrect perception of
short-term CVD risk was not uncommon due to an ‘opti-
mism bias’, in which people (and even physicians) gener-
ally underestimate their personal risk for CVD [51]. A
recent paper [52] reported the perceived lifetime risk for
CVD in the general population, demonstrating that the
perception of lifetime risk for CVD is often also inaccurate
and generally mainly influenced by personal factors (i.e.,
subjective perception of stress and personal health) com-
pared with traditional CV RFs. Despite most study par-
ticipants (64 %) having a high predicted lifetime risk for
CVD, most did not perceive themselves as being at high
risk. This evidence is alarming. In fact, it has been shown
that patients’ awareness of CV risk level is a motivating
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factor for them to make lifestyle changes and eventually to
adhere to pharmacological treatment with BP and choles-
terol-lowering medications, resulting in a reduction in CV
RF burden [52]. Self-perception of low CVD risk, in con-
trast, decreases motivation to engage in lifestyle modifi-
cation and has deleterious influence on the acceptance of
and adherence to pharmacological treatment. Thus, it is
important to introduce population-level education pro-
grams, and to develop easy and cheap tools to assess CV
risk, for example, a calculator of lifetime risk, such as that
recently developed by the British Joint Societies to help
patients become aware of their actual lifetime CV risk [53].
5 The Polypill Approach
Following the assumption that preventing RF from
emerging is probably more effective than treating them
once they are established, a decade ago a novel preventive
approach was proposed: pharmacotherapy with multiple
drugs combined in a single preparation, called a ‘polypill’
[54, 55]. This is clearly not an example of an integrated
preventive approach, but it does represent a widely man-
ageable tool for ‘high-risk’ targeted preventive strategies.
As originally described by Wald and Law [54], the polypill
contained three antihypertensive drugs (e.g., thiazide di-
uretics, beta-blockers, angiotensin-converting enzyme
[ACE] inhibitors, angiotensin receptor blockers [ARBs],
and calcium channel blockers) at half a standard dose, low-
to moderate-dose statin (e.g., atorvastatin 10 mg or sim-
vastatin 20–40 mg), folic acid, and low-dose aspirin. Based
on the results of previous meta-analyses [56, 57], they
estimated that this six-component polypill, with full ad-
herence to preventive treatment, would reduce an indi-
vidual’s risk of coronary heart disease and stroke by about
80 % [54].
A large level of evidence supports the use of pharma-
cological treatment for the secondary prevention of CVD in
patients with prior CV events. Antiplatelet agents, beta-
blockers, lipid-lowering agents, and ACE inhibitors have
all individually demonstrated improvements in mortality
and morbidity and are recommended for secondary pre-
vention of CVD by a diverse group of professional orga-
nizations. However, in spite of well-documented
international guidelines, there are still substantial gaps in
terms of the adequate use of secondary interventions for
prevention of CVD [32]. More than half of patients with
prior ischemic heart disease or stroke receive no secondary
medications, and\10 % receive three of the four proven
medications. This situation is much worse in LMICs, where
more than three out of four patients with CVD take no
medication. Reasons for this include limited access to
health practitioners, inadequate prescription of medicines,
incomplete awareness of the importance of lifelong therapy
by both physicians and patients, poor adherence, lack of
availability of key medications and unaffordable costs of
even generic drugs compared with local incomes. Fixed-
dose combination (FDC) therapy that combines CVD
secondary preventive medicines appears to overcome many
of these barriers, as shown in large trials such as TIPS (The
Indian Polycap Study) conducted in LMICs [58]. In par-
ticular, FDC therapy has been shown to improve adherence
by 33 % compared with usual care in CVD secondary
prevention [59]. Thus, CVD secondary prevention with
polypill therapy has been deemed a ‘‘best buy’’ by the
WHO [60], given its efficacy, adherence, scalability, and
cost effectiveness.
With regard to primary prevention, in view of the fact
that age is the strongest predictor of adverse CV events
[61], Wald and Law [54] proposed that anyone aged
[55 years, regardless of their starting RF levels, should
use preventive treatment. In other words, treatment should
not be limited to people with ‘hypertension’ or ‘hy-
percholesterolemia’, but everyone above a specified age
(e.g., 55 years) should receive the polypill, regardless of
their individual RF profile.
The polypill has been shown to significantly reduce both
serum cholesterol and BP, while issues in terms of adher-
ence and tolerability of the polypill remain [62–65]. The
HOPE (Heart Outcomes Prevention Evaluation)-3 trial is
evaluating the concept of combined BP and cholesterol-
lowering for 6 years in 12,705 individuals from five con-
tinents without known CVD but at moderate CVD risk. All
participants receive structured lifestyle advice; primary
outcomes are CVD events and secondary outcomes are
cognitive and renal function, with results expected in 2016
[66]. The TIPS-3 trial will include 5500 individuals from
India, the Philippines, Canada, China, Brazil, Argentina,
Chile, Colombia, and additional countries. The aim of the
study is to estimate the impact on major CVD events of a
four-drug combination pill versus placebo in a primary
prevention population over 5 years. The participants are
men aged[55 years and women aged[60 years without
CVD and with an elevated INTERHEART risk score of
C10 (which corresponds to a projected annual CV event
rate in the control group of 0.1 %) [67]. The HOPE-4
community cluster randomized trial will evaluate an evi-
dence-based program for CVD risk assessment, treatment,
and control involving simplified screening and treatment
algorithms implemented by non-physician health workers
(often public health nurses or nursing assistants) coupled
with lifestyle counselling and combination-pill therapy.
The initial risk factor phase of the study will assess BP and
cholesterol changes in Colombia and Malaysia (50 com-
munities), with plans to expand to 190 communities in
eight countries to evaluate CVD events over 6 years [68].
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The PolyIran open-label cluster randomized controlled trial
aims to determine the effects of a combination pill versus
minimal care in primary and secondary prevention of CVD
in 7000 adults aged 50–79 years from Iran. The primary
outcome at 5 years is the time to first major CV event, and
the results are expected in 2018 or 2019 [69].
Many issues remain to be addressed regarding the use of
the polypill. The first is to determine the ideal pharma-
ceutical formulation of the polypill. The value of aspirin in
primary prevention continues to be debated, as the modest
reduction in CV events is counterbalanced by an increased
incidence of major bleeds [70]. Thus, a polypill used for
primary prevention of CVD should not include aspirin [71],
although recent data showing that aspirin reduces the in-
cidence of cancer could substantially modify this risk–
benefit ratio [72, 73]. Polypill adherence issues and the
acceptance of the polypill by both patients and physicians
will need to be addressed. Indeed, as a treatment for pri-
mary prevention in ‘healthy’ subjects who may not be
motivated to use medications long term, it is important to
consider that even minor side effects to one component of
the polypill may cause its discontinuation and hence loss of
benefit from all component drugs. Emphasis on education
about CV prevention, low cost, and tolerability is of key
importance for the acceptance of the polypill by both pa-
tients and physicians.
Finally, a concern related to the use of combination
therapy is that it would replace efforts to promote healthy
lifestyles and that the entire populationmay be unnecessarily
‘medicalized’ upon age criteria alone. Indeed, if treating
when benefit outweighs harm is accepted, treating risk rather
than RF thresholds may not be easily agreed upon.
However, many people with clinically defined hyper-
tension or dyslipidemia are not aware of these conditions,
thus treating everyone reduces the possibility of CVD due
to unrecognized risk [74]. Moreover, by avoiding complex
algorithms to identify individuals at high CV risk who
require therapy, and by increasing the ease of prescribing,
costs of screening may be considerably diminished, so that
more at-risk individuals can be treated. This strategy also
permits the prevention of the numerous CV events that
occur in people with a mild burden of known RFs who are
not included in the high-risk group. These considerations
are of particular importance for people living in developing
countries who currently receive little or no preventive care.
In addition, a polypill might represent a useful strategy to
improve adherence to pharmacological therapy, thereby
reducing costs [75, 76].
We can conclude that, although the polypill has been
suggested as a simple and largely useful means of pre-
vention, its target population has not yet been recognized,
and its cost effectiveness, not only in terms of efficacy on
CV hard endpoints in the long term but also in terms of side
effects, adherence rates, ethical concerns, and economic
burden, is still debated.
6 Conclusion
While advances in medical research over the last century
have resulted in a significant decrease of CVD-related
mortality, it remains the leading cause of death and mor-
bidity, particularly in western countries. The prevention
strategies conducted so far have achieved positive results;
however, these results are far from satisfactory. These
days, the perceived dualism between population-based
strategies and a ‘high-risk’ approach is obsolete and should
be overcome with the promotion of an integrated preven-
tion strategy. Based on data collected so far, it seems that
policy choices in clinical prevention can be improved
based on the total risk of disease at both a population and
an individual level. Easy estimation of CVD lifetime risk
could help progression into a more modern age of CVD
prevention, thus increasing the spread of useful therapeutic
measures.
The polypill could be a way forward, but still lacks
evidence, mostly with regards to its effect on mortality and
morbidity in the long term. Future studies should be con-
ducted to assess the net benefits of this strategy on major
CV events.
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